{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T06:10:09Z","timestamp":1737267009367,"version":"3.33.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Institute","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]},{"name":"Sabin Family Fellowship Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-024-01145-0","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T17:36:25Z","timestamp":1737221785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1007","volume":"56","author":[{"given":"Enoch","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander D.","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Liermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Wei D.","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene J.","family":"Koay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajnan","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert C.","family":"Koong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan B.","family":"Ludmir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"issue":"1","key":"1145_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8\u201310.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1145_CR2","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18\u201328.","journal-title":"Lancet Oncol"},{"issue":"18","key":"1145_CR3","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558\u201365.","journal-title":"J Clin Oncol"},{"issue":"10185","key":"1145_CR4","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051\u20138.","journal-title":"Lancet"},{"issue":"1","key":"1145_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2468-1253(23)00316-3","volume":"9","author":"Q Liu","year":"2024","unstructured":"Liu Q, Chen J, Lin Y, Ye J, Shen W, Luo H, Li B, Huang W, Wei S, Song J, et al. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024;9(1):45\u201355.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1145_CR6","doi-asserted-by":"crossref","unstructured":"Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109(9).","DOI":"10.1093\/jnci\/djx015"},{"issue":"5","key":"1145_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446\u201353.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1145_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650\u20139.","journal-title":"JAMA Oncol"},{"issue":"29","key":"1145_CR9","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40(29):3377\u201382.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1145_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","volume":"9","author":"C Tang","year":"2023","unstructured":"Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol. 2023;9(6):825\u201334.","journal-title":"JAMA Oncol"},{"issue":"36","key":"1145_CR11","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, Ingrosso G, D\u2019Angelillo RM, Alitto AR, Augugliaro M, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol. 2023;41(36):5561\u20138.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1145_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","volume":"40","author":"SJ Chmura","year":"2022","unstructured":"Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, Matuszak M, Milano MT, Jaskowiak NT, Bandos H, et al. NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol. 2022;40(16_suppl):1007\u20131007.","journal-title":"J Clin Oncol"},{"key":"1145_CR13","doi-asserted-by":"crossref","unstructured":"Reddy JP, Sherry AD, Fellman B, Liu S, Bathala T, Haymaker C, Cohen L, Smith BD, Ramirez D, Shaitelman SF, et al. Adding metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic breast cancer (EXTEND): a multicenter, randomized phase II trial. Int J Radiat Oncol Biol Phys. 2024.","DOI":"10.1016\/j.ijrobp.2024.10.030"},{"issue":"16_suppl","key":"1145_CR14","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","volume":"42","author":"P Iyengar","year":"2024","unstructured":"Iyengar P, Hu C, Gomez DR, Timmerman RD, Simone CB, Robinson CG, Gerber DE, Waqar SN, Donington J, Swisher S, et al. NRG-LU002: randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2024;42(16_suppl):8506\u20138506.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1145_CR15","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501.","journal-title":"JAMA Oncol"},{"issue":"10","key":"1145_CR16","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(18)30571-0","volume":"19","author":"FE Lecouvet","year":"2018","unstructured":"Lecouvet FE, Oprea-Lager DE, Liu Y, Ost P, Bidaut L, Collette L, Deroose CM, Goffin K, Herrmann K, Hoekstra OS, et al. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncol. 2018;19(10):e534\u201345.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1145_CR17","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","volume":"14","author":"AC Dingemans","year":"2019","unstructured":"Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, et al. Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report. J Thorac Oncol. 2019;14(12):2109\u201319.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1145_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2013.07.026","volume":"82","author":"A Ashworth","year":"2013","unstructured":"Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82(2):197\u2013203.","journal-title":"Lung Cancer"},{"issue":"12","key":"1145_CR19","doi-asserted-by":"publisher","first-page":"e50141","DOI":"10.1371\/journal.pone.0050141","volume":"7","author":"YA Lussier","year":"2012","unstructured":"Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich JL, Darga TE, Fan H, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012;7(12):e50141.","journal-title":"PLoS One"},{"issue":"12","key":"1145_CR20","doi-asserted-by":"publisher","first-page":"e28650","DOI":"10.1371\/journal.pone.0028650","volume":"6","author":"YA Lussier","year":"2011","unstructured":"Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6(12):e28650.","journal-title":"PLoS One"},{"issue":"12","key":"1145_CR21","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s00345-018-2609-8","volume":"37","author":"B Dhondt","year":"2019","unstructured":"Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, Beckers A, Fonteyne V, Van der Eecken K, De Bruycker A, et al. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. World J Urol. 2019;37(12):2557\u201364.","journal-title":"World J Urol"},{"issue":"1","key":"1145_CR22","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41467-018-04278-6","volume":"9","author":"SP Pitroda","year":"2018","unstructured":"Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, et al. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018;9(1):1793.","journal-title":"Nat Commun"},{"issue":"1","key":"1145_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41698-023-00440-6","volume":"7","author":"NP Semenkovich","year":"2023","unstructured":"Semenkovich NP, Badiyan SN, Samson PP, Stowe HB, Wang YE, Star R, Devarakonda S, Govindan R, Waqar SN, Robinson CG, et al. Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer. NPJ Precis Oncol. 2023;7(1):100.","journal-title":"NPJ Precis Oncol"},{"key":"1145_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Mendez Romero A, Nevens D, Palma D, Park C, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157\u201366.","journal-title":"Radiother Oncol"},{"issue":"3","key":"1145_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ijrobp.2020.05.018","volume":"108","author":"JB Yu","year":"2020","unstructured":"Yu JB, Brock KK, Campbell AM, Chen AB, Diaz R, Escorcia FE, Gupta G, Hrinivich WT, Joseph S, Korpics M, et al. Proceedings of the ASTRO-RSNA oligometastatic disease research workshop. Int J Radiat Oncol Biol Phys. 2020;108(3):539\u201345.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1145_CR26","doi-asserted-by":"publisher","first-page":"102067","DOI":"10.1016\/j.esmoop.2023.102067","volume":"8","author":"CS Leonhardt","year":"2023","unstructured":"Leonhardt CS, Stamm T, Hank T, Prager G, Strobel O. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. ESMO Open. 2023;8(6):102067.","journal-title":"ESMO Open"},{"issue":"19","key":"1145_CR27","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"18","key":"1145_CR28","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"10409","key":"1145_CR29","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardiere C, Dean A, Kiss I, Lee WJ, Goetze TO, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272\u201381.","journal-title":"Lancet"},{"issue":"12","key":"1145_CR30","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","volume":"22","author":"C Tang","year":"2021","unstructured":"Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021;22(12):1732\u20139.","journal-title":"Lancet Oncol"},{"issue":"1106","key":"1145_CR31","doi-asserted-by":"publisher","first-page":"20190627","DOI":"10.1259\/bjr.20190627","volume":"93","author":"M Scorsetti","year":"2020","unstructured":"Scorsetti M, Comito T, Franceschini D, Franzese C, Prete MG, D\u2019Alessio A, Bozzarelli S, Rimassa L, Santoro A. Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. Br J Radiol. 2020;93(1106):20190627.","journal-title":"Br J Radiol"},{"issue":"1","key":"1145_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.surg.2016.02.019","volume":"160","author":"M Tachezy","year":"2016","unstructured":"Tachezy M, Gebauer F, Janot M, Uhl W, Zerbi A, Montorsi M, Perinel J, Adham M, Dervenis C, Agalianos C, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160(1):136\u201344.","journal-title":"Surgery"},{"issue":"2","key":"1145_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ejso.2016.10.023","volume":"43","author":"T Hackert","year":"2017","unstructured":"Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A, Michalski CW, Buchler MW. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43(2):358\u201363.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"1145_CR34","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1097\/MPA.0000000000001822","volume":"50","author":"G Lee","year":"2021","unstructured":"Lee G, Kim DW, Oladeru OT, Niemierko A, Gergelis KR, Haddock MG, Toesca DAS, Koong AJ, Owen D, Weekes C, et al. Liver metastasis-directed ablative radiotherapy in pancreatic cancer offers prolonged time off systemic therapy in selected patients: data from a multi-institutional retrospective study. Pancreas. 2021;50(5):736\u201343.","journal-title":"Pancreas"},{"issue":"4","key":"1145_CR35","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ijrobp.2022.07.019","volume":"114","author":"AM Elamir","year":"2022","unstructured":"Elamir AM, Karalis JD, Sanford NN, Polanco PM, Folkert MR, Porembka MR, Kazmi SA, Maddipati R, Zeh HJ, Timmerman RD, et al. Ablative radiation therapy in oligometastatic pancreatic cancer to delay polyprogression, limit chemotherapy, and improve outcomes. Int J Radiat Oncol Biol Phys. 2022;114(4):792\u2013802.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"1145_CR36","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/jhbp.1303","volume":"30","author":"M Nagai","year":"2023","unstructured":"Nagai M, Wright MJ, Ding D, Thompson ED, Javed AA, Weiss MJ, Hruban RH, Yu J, Burkhart RA, He J, et al. Oncologic resection of pancreatic cancer with isolated liver metastasis: favorable outcomes in select patients. J Hepatobiliary Pancreat Sci. 2023;30(8):1025\u201335.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1145_CR37","doi-asserted-by":"crossref","unstructured":"Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, Medina-Rosales MN, Reuben A, Holliday EB, Smith GL, et al. Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): a multicenter, randomized phase II trial. J Clin Oncol. 2024;JCO2400081.","DOI":"10.1200\/JCO.2024.42.3_suppl.603"},{"key":"1145_CR38","unstructured":"Extending outcomes for pancreas cancer patients with nominal oligometastatic disease (EXPAND): a randomized phase III trial.\u00a0[https:\/\/clinicaltrials.gov\/study\/NCT06593431]."},{"issue":"16","key":"1145_CR39","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","volume":"18","author":"C Feig","year":"2012","unstructured":"Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18(16):4266\u201376.","journal-title":"Clin Cancer Res"},{"issue":"38","key":"1145_CR40","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1038\/s41388-022-02425-4","volume":"41","author":"B Diskin","year":"2022","unstructured":"Diskin B, Adam S, Soto GS, Liria M, Aykut B, Sundberg B, Li E, Leinwand J, Chen R, Kim M, et al. BTLA(+)CD200(+) B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. Oncogene. 2022;41(38):4349\u201360.","journal-title":"Oncogene"},{"issue":"1","key":"1145_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/1078-0432.CCR-21-2495","volume":"28","author":"BN Mills","year":"2022","unstructured":"Mills BN, Qiu H, Drage MG, Chen C, Mathew JS, Garrett-Larsen J, Ye J, Uccello TP, Murphy JD, Belt BA, et al. Modulation of the human pancreatic ductal adenocarcinoma immune microenvironment by stereotactic body radiotherapy. Clin Cancer Res. 2022;28(1):150\u201362.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1145_CR42","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, Thel H, Hoyos D, Mehta A, Arshad S, et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021;2(11):1124\u201335.","journal-title":"Nat Cancer"},{"issue":"5","key":"1145_CR43","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ccell.2023.04.001","volume":"41","author":"M Piper","year":"2023","unstructured":"Piper M, Hoen M, Darragh LB, Knitz MW, Nguyen D, Gadwa J, Durini G, Karakoc I, Grier A, Neupert B, et al. Simultaneous targeting of PD-1 and IL-2Rbetagamma with radiation therapy inhibits pancreatic cancer growth and metastasis. Cancer Cell. 2023;41(5):950-969 e956.","journal-title":"Cancer Cell"},{"issue":"6","key":"1145_CR44","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/j.prro.2020.01.012","volume":"10","author":"EJ Koay","year":"2020","unstructured":"Koay EJ, Hanania AN, Hall WA, Taniguchi CM, Rebueno N, Myrehaug S, Aitken KL, Dawson LA, Crane CH, Herman JM, et al. Dose-escalated radiation therapy for pancreatic cancer: a simultaneous integrated boost approach. Pract Radiat Oncol. 2020;10(6):e495\u2013507.","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"1145_CR45","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","volume":"94","author":"S Krishnan","year":"2016","unstructured":"Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, Minsky BD, Mahmood U, Delclos ME, Sawakuchi GO, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94(4):755\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1145_CR46","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.adro.2017.02.004","volume":"2","author":"LE Colbert","year":"2017","unstructured":"Colbert LE, Moningi S, Chadha A, Amer A, Lee Y, Wolff RA, Varadhachary G, Fleming J, Katz M, Das P, et al. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol. 2017;2(3):403\u201315.","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"1145_CR47","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","volume":"7","author":"M Reyngold","year":"2021","unstructured":"Reyngold M, O\u2019Reilly EM, Varghese AM, Fiasconaro M, Zinovoy M, Romesser PB, Wu A, Hajj C, Cuaron JJ, Tuli R, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. JAMA Oncol. 2021;7(5):735\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1145_CR48","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.radonc.2017.05.013","volume":"124","author":"WG Campbell","year":"2017","unstructured":"Campbell WG, Jones BL, Schefter T, Goodman KA, Miften M. An evaluation of motion mitigation techniques for pancreatic SBRT. Radiother Oncol. 2017;124(1):168\u201373.","journal-title":"Radiother Oncol"},{"issue":"5","key":"1145_CR49","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","volume":"9","author":"M Palta","year":"2019","unstructured":"Palta M, Godfrey D, Goodman KA, Hoffe S, Dawson LA, Dessert D, Hall WA, Herman JM, Khorana AA, Merchant N, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2019;9(5):322\u201332.","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"1145_CR50","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13014-019-1361-6","volume":"14","author":"GW Choi","year":"2019","unstructured":"Choi GW, Suh Y, Das P, Herman J, Holliday E, Koay E, Koong AC, Krishnan S, Minsky BD, Smith GL, et al. Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration-based image guidance. Radiat Oncol. 2019;14(1):154.","journal-title":"Radiat Oncol"},{"issue":"4","key":"1145_CR51","doi-asserted-by":"publisher","first-page":"101164","DOI":"10.1016\/j.adro.2022.101164","volume":"8","author":"DJ Rhee","year":"2023","unstructured":"Rhee DJ, Beddar S, Jaoude JA, Sawakuchi G, Martin R, Perles L, Yu C, He Y, Court LE, Ludmir EB, et al. Dose escalation for pancreas SBRT: potential and limitations of using daily online adaptive radiation therapy and an iterative isotoxicity automated planning approach. Adv Radiat Oncol. 2023;8(4):101164.","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"1145_CR52","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","volume":"117","author":"PJ Parikh","year":"2023","unstructured":"Parikh PJ, Lee P, Low DA, Kim J, Mittauer KE, Bassetti MF, Glide-Hurst CK, Raldow AC, Yang Y, Portelance L, et al. A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2023;117(4):799\u2013808.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1145_CR53","doi-asserted-by":"publisher","first-page":"110064","DOI":"10.1016\/j.radonc.2023.110064","volume":"191","author":"MD Chuong","year":"2024","unstructured":"Chuong MD, Lee P, Low DA, Kim J, Mittauer KE, Bassetti MF, Glide-Hurst CK, Raldow AC, Yang Y, Portelance L, et al. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study. Radiother Oncol. 2024;191:110064.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1145_CR54","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijrobp.2024.03.013","volume":"120","author":"LT Tchelebi","year":"2024","unstructured":"Tchelebi LT, Segovia D, Smith K, Shi Q, Fitzgerald TJ, Chuong MD, Zemla TJ, O\u2019Reilly EM, Meyerhardt JA, Koay EJ, et al. Radiation therapy quality assurance analysis of alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2024;120(1):111\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1145_CR55","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1245\/s10434-008-0295-2","volume":"16","author":"MH Katz","year":"2009","unstructured":"Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(4):836\u201347.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1145_CR56","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/jhbp.1127","volume":"29","author":"Y Homma","year":"2022","unstructured":"Homma Y, Endo I, Matsuyama R, Sho M, Mizuno S, Seyama Y, Hirano S, Aono T, Kitami C, Morita Y, et al. Outcomes of lung metastasis from pancreatic cancer: a nationwide multicenter analysis. J Hepatobiliary Pancreat Sci. 2022;29(5):552\u201361.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"1","key":"1145_CR57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","volume":"261","author":"CR Ferrone","year":"2015","unstructured":"Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12\u20137.","journal-title":"Ann Surg"},{"issue":"23","key":"1145_CR58","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1002\/cncr.27636","volume":"118","author":"MH Katz","year":"2012","unstructured":"Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749\u201356.","journal-title":"Cancer"},{"issue":"9","key":"1145_CR59","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.6004\/jnccn.2022.7041","volume":"20","author":"AM Abdelrahman","year":"2022","unstructured":"Abdelrahman AM, Goenka AH, Alva-Ruiz R, Yonkus JA, Leiting JL, Graham RP, Merrell KW, Thiels CA, Hallemeier CL, Warner SG, et al. FDG-PET predicts neoadjuvant therapy response and survival in borderline resectable\/locally advanced pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2022;20(9):1023-1032 e1023.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1145_CR60","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/1078-0432.CCR-16-0806","volume":"23","author":"D Pietrasz","year":"2017","unstructured":"Pietrasz D, Pecuchet N, Garlan F, Didelot A, Dubreuil O, Doat S, Imbert-Bismut F, Karoui M, Vaillant JC, Taly V, et al. Plasma circulating tumor dna in pancreatic cancer patients is a prognostic marker. Clin Cancer Res. 2017;23(1):116\u201323.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1145_CR61","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-19-0197","volume":"25","author":"VP Groot","year":"2019","unstructured":"Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, et al. Circulating tumor DNA as a clinical test in resected pancreatic cancer. Clin Cancer Res. 2019;25(16):4973\u201384.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1145_CR62","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24(6):1344\u201354.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1145_CR63","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","volume":"27","author":"CA Iacobuzio-Donahue","year":"2009","unstructured":"Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11):1806\u201313.","journal-title":"J Clin Oncol"},{"key":"1145_CR64","doi-asserted-by":"publisher","unstructured":"Wyatt AW, Litiere S, Bidard FC, Cabel L, Dyrskjot L, Karlovich CA, Pantel K, Petrie J, Philip R, Andrews HS et al. Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group. Clin Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1883.","DOI":"10.1158\/1078-0432.CCR-24-1883"},{"key":"1145_CR65","doi-asserted-by":"crossref","unstructured":"Roberts HJ, Weekes CD, Wo JY. Establishing a role for local therapy in oligometastatic pancreatic cancer. J Clin Oncol. 2024;JCO2401264.","DOI":"10.1200\/JCO-24-01264"},{"issue":"12","key":"1145_CR66","doi-asserted-by":"publisher","first-page":"e033452","DOI":"10.1136\/bmjopen-2019-033452","volume":"9","author":"M Wei","year":"2019","unstructured":"Wei M, Shi S, Hua J, Xu J, Yu X, Chinese Study Group for Pancreatic C. Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open. 2019;9(12):e033452.","journal-title":"BMJ Open"},{"issue":"16_suppl","key":"1145_CR67","doi-asserted-by":"publisher","first-page":"TPS4207","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4207","volume":"42","author":"P Jo","year":"2024","unstructured":"Jo P, Ghadimi M, Pelzer U, Crede M-TA, Telgmann R, Seppanen H, Bratlie SO, Besselink MG, Friede T, Siveke JT. METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer: multimodal surgical treatment versus systemic chemotherapy alone\u2014a prospective randomized controlled multicenter phase III trial. J Clin Oncol. 2024;42(16_suppl):TPS4207\u2013TPS4207.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1145_CR68","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12885-021-08966-3","volume":"21","author":"F Gebauer","year":"2021","unstructured":"Gebauer F, Damanakis AI, Popp F, Quaas A, Kutting F, Lutz K, Held S, Deuss B, Goser T, Waldschmidt D, et al. Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil\/Folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer. 2021;21(1):1239.","journal-title":"BMC Cancer"},{"issue":"10422","key":"1145_CR69","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of radiotherapy to block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403(10422):171\u201382.","journal-title":"Lancet"},{"key":"1145_CR70","unstructured":"A randomized phase II basket trial EXTENDing efficacy of systemic therapy with local consolidative therapy for oligoprogressive metastatic disease (EXTEND-OP).\u00a0[https:\/\/clinicaltrials.gov\/study\/NCT06367972]."}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-024-01145-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T05:29:28Z","timestamp":1737264568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-024-01145-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s12029-024-01145-0","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"type":"print","value":"1941-6628"},{"type":"electronic","value":"1941-6636"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"10 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.D. Sherry reports honoraria from Sermo. C.D. Tzeng reports research grants from Sirtex and consulting fees from PanTher. C. Tang reports grants from the Cancer Prevention & Research Institute of Texas (CPRIT), Noxopharm, and the Department of Defense (DoD), receiving royalties from Wolters Kluwer and Osler Institute, and receiving and consulting fees and honoraria from Siemen Healthineer, Lantheus, Telix, Molli Surgical, and Boston Scientific. T. A. Aguilera reports grants from the National Institutes of Health, royalties from UC San Diego and Stanford, and stock from Avelas Biosciences. E.J. Koay reports grants from National Institutes of Health, Stand Up 2 Cancer, MD Anderson Cancer Center, Philips Healthcare, Elekta, and GE Healthcare; personal fees from RenovoRx and Taylor and Francis; and a consulting\/advisory role with Augmenix. P. Das reports honoraria from Bayer and ASTRO. S. Pant reports consulting fees from Zymeworks, Ipsen, Novartis, Janssen, Boehringer Ingelheim, AskGene Pharma, BPGbio, Jazz Pharmaceuticals, AstraZeneca, US WorldMeds, Nihon Medi-Physics, Alligator Bioscience, and research funding from Mirati Therapeutics, Lilly, Xencor, Novartis, Rgenix, Bristol Myers Squibb, Astellas Pharma, Purple Biotech, 4D Pharma, Boehringer Ingelheim, NGM Biopharmaceuticals, Janssen, Arcus Biosciences, Elicio Therapeutics, Bionte, Ipsen, Zymeworks, Pfizer, ImmunoMET, Immuneering, and Amal Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"47"}}